Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis
Abstract The possible effects of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) on COVID-19 disease severity have generated considerable debate. We performed a single-center, retrospective analysis of hospitalized adult COVID-19 patients in Wuhan, China, who had definite clinical outcome (dead or discharged) by February 15, 2020. Patients on anti-hypertensive treatment with or without ACEI/ARB were compared on their clinical characteristics and outcomes. The medical records from 702 patients were screened. Among the 101 patients with a history of hypertension and taking at least one anti-hypertensive medication, 40 patients were receiving ACEI/ARB as part of their regimen, and 61 patients were on antihypertensive medication other than ACEI/ARB. We observed no statistically significant differences in percentages of in-hospital mortality (28% vs. 34%, P = 0.46), ICU admission (20% vs. 28%, P = 0.37) or invasive mechanical ventilation (18% vs. 26%, P = 0.31) between patients with or without ACEI/ARB treatment. Further multivariable adjustment of age and gender did not provide evidence for a significant association between ACEI/ARB treatment and severe COVID-19 outcomes. Our findings confirm the lack of an association between chronic receipt of renin-angiotensin system antagonists and severe outcomes of COVID-19. Patients should continue previous anti-hypertensive therapy until further evidence is available..
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
---|---|
Enthalten in: |
Frontiers of medicine - 14(2020), 5 vom: 03. Juli, Seite 601-612 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Xu, Jiuyang [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
Angiotensin II receptor blocker |
---|
Anmerkungen: |
© Higher Education Press 2020 |
---|
doi: |
10.1007/s11684-020-0800-y |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC2120208638 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | OLC2120208638 | ||
003 | DE-627 | ||
005 | 20240404064432.0 | ||
007 | tu | ||
008 | 230504s2020 xx ||||| 00| ||eng c | ||
024 | 7 | |a 10.1007/s11684-020-0800-y |2 doi | |
035 | |a (DE-627)OLC2120208638 | ||
035 | |a (DE-He213)s11684-020-0800-y-p | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
100 | 1 | |a Xu, Jiuyang |e verfasserin |4 aut | |
245 | 1 | 0 | |a Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a © Higher Education Press 2020 | ||
520 | |a Abstract The possible effects of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) on COVID-19 disease severity have generated considerable debate. We performed a single-center, retrospective analysis of hospitalized adult COVID-19 patients in Wuhan, China, who had definite clinical outcome (dead or discharged) by February 15, 2020. Patients on anti-hypertensive treatment with or without ACEI/ARB were compared on their clinical characteristics and outcomes. The medical records from 702 patients were screened. Among the 101 patients with a history of hypertension and taking at least one anti-hypertensive medication, 40 patients were receiving ACEI/ARB as part of their regimen, and 61 patients were on antihypertensive medication other than ACEI/ARB. We observed no statistically significant differences in percentages of in-hospital mortality (28% vs. 34%, P = 0.46), ICU admission (20% vs. 28%, P = 0.37) or invasive mechanical ventilation (18% vs. 26%, P = 0.31) between patients with or without ACEI/ARB treatment. Further multivariable adjustment of age and gender did not provide evidence for a significant association between ACEI/ARB treatment and severe COVID-19 outcomes. Our findings confirm the lack of an association between chronic receipt of renin-angiotensin system antagonists and severe outcomes of COVID-19. Patients should continue previous anti-hypertensive therapy until further evidence is available. | ||
650 | 4 | |a COVID-19 | |
650 | 4 | |a SARS-CoV-2 | |
650 | 4 | |a hypertension | |
650 | 4 | |a angiotensin-converting enzyme inhibitor | |
650 | 4 | |a angiotensin II receptor blocker | |
700 | 1 | |a Huang, Chaolin |4 aut | |
700 | 1 | |a Fan, Guohui |4 aut | |
700 | 1 | |a Liu, Zhibo |4 aut | |
700 | 1 | |a Shang, Lianhan |4 aut | |
700 | 1 | |a Zhou, Fei |4 aut | |
700 | 1 | |a Wang, Yeming |4 aut | |
700 | 1 | |a Yu, Jiapei |4 aut | |
700 | 1 | |a Yang, Luning |4 aut | |
700 | 1 | |a Xie, Ke |4 aut | |
700 | 1 | |a Huang, Zhisheng |4 aut | |
700 | 1 | |a Huang, Lixue |4 aut | |
700 | 1 | |a Gu, Xiaoying |4 aut | |
700 | 1 | |a Li, Hui |4 aut | |
700 | 1 | |a Zhang, Yi |4 aut | |
700 | 1 | |a Wang, Yimin |4 aut | |
700 | 1 | |a Hayden, Frederick G. |4 aut | |
700 | 1 | |a Horby, Peter W. |4 aut | |
700 | 1 | |a Cao, Bin |4 aut | |
700 | 1 | |a Wang, Chen |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Frontiers of medicine |d Higher Education Press, 2011 |g 14(2020), 5 vom: 03. Juli, Seite 601-612 |w (DE-627)671806890 |w (DE-600)2636271-5 |w (DE-576)352909021 |x 2095-0217 |7 nnns |
773 | 1 | 8 | |g volume:14 |g year:2020 |g number:5 |g day:03 |g month:07 |g pages:601-612 |
856 | 4 | 1 | |u https://doi.org/10.1007/s11684-020-0800-y |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_2018 | ||
951 | |a AR | ||
952 | |d 14 |j 2020 |e 5 |b 03 |c 07 |h 601-612 |